Tag Archive | "Cubist"

Merck acquires Cubist Pharmaceuticals for $9.5bn

Tags: , , ,


Merck and Cubist Pharmaceuticals have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash, which represents a 35 percent premium to Cubist’s average stock price for the most recent five trading days. Read the full story

Partnering Agreements with Cubist

Tags: ,


The Partnering Agreements with Cubist report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies. Read the full story

Cubist Pharma, the next acquisition target for big pharmaceuticals

Tags: , ,


The timing may be right for a takeover of Cubist Pharmaceuticals. Read the full story

Cubist Pharmaceuticals – Shaping developments in antibiotics

Tags: , ,


Cubist Pharmaceuticals is a biopharmaceutical company developing and commercializing medications for acute care in hospitals and surgical environments. Read the full story

Cubist: Partnering activity 2009-2014

Tags: , ,


Cubist, a leading biopharmaceutical company focusses in the discovery, development and commercialization of novel acute care therapies. Read the full story

Cubist expands financing round to $800 million offering

Tags: , , ,


Cubist Pharmaceuticals has upped the size of its financing offering of convertible notes to as much at $800 million, including overallotments, to pay for its acquisition of Optimer Pharmaceuticals. Read the full story

Cubist announces financing of $600m in convertible senior notes

Tags: , ,


Big biotech, Cubist Pharmaceuticals, announced its intention to commence a financing offering, subject to market and other conditions, of $600 million in convertible senior unsecured notes that are expected to be issued in two $300 million series Read the full story

Cubist seals merger and acquisition activity with Optimer buy

Tags: , ,


Cubist Pharmaceuticals and Optimer Pharmaceuticals seal merger and acquisition activity under which Cubist will acquire all of the outstanding shares of Optimer common stock for $10.75 per share in cash, or approximately $535 million on a fully diluted basis Read the full story

Cubist creates M&A news with Trius Therapeutics buy

Tags: ,


M&A news: Cubist Pharmaceuticals,  and Trius Therapeutics have signed a definitive agreement under which Cubist will acquire all outstanding shares of Trius for $13.50 per share in cash or approximately $707 million on a fully diluted basis Read the full story

Cubist Pharmaceuticals in pharma licensing pact with Astellas Pharma

Tags: , , , ,


Cubist Pharmaceuticals and Astellas Pharma have entered into a pharma licensing agreement under which Cubist obtains the rights to ceftolozane in certain Asia-Pacific and Middle East territories from Astellas. Read the full story